To evaluate PD-L1 expression, we consecutively enrolled 138 NSCLC patients with definite histopathological diagnosis, sufficient tumor specimens and adequate clinical data, as well as follow up information, whose baseline characteristics were concisely presented in Table 1. This evidence concerns the gene CD274 and neoplasm.